FDA WARNING_LETTER - Canada Med Stop - August 01, 2025

On September 9, 2025, the U.S. Food and Drug Administration (FDA) issued a warning letter to Canada Med Stop after reviewing the company’s website in August 2025. The investigation revealed that the company is marketing compounded semaglutide products using false and misleading information. Specifically, the website incorrectly describes these products as "FDA-Approved" and "Generic," while claiming they contain the "same active ingredient" as branded weight-loss medications. The FDA emphasizes that compounded drugs do not undergo the same approval process as standard medications, making these claims deceptive to consumers. Under the Federal Food, Drug, and Cosmetic Act, these products are considered misbranded because their labeling and promotional materials are inaccurate. Distributing misbranded drugs across state or international lines is a violation of federal law. To resolve these issues, Canada Med Stop must immediately cease using the misleading language and ensure all operations comply with federal regulations. The company is required to submit a written response to the FDA within 15 working days, outlining the corrective actions taken and the measures implemented to prevent future violations. Failure to provide an adequate response may lead to legal action, including product seizures or a ban on importing the products into the United States.